PEMETREXED, VINORELBINE, Rilvegostomig, MYCOPHENOLATE MOFETIL, ETOPOSIDE, CISPLATIN, INFLIXIMAB, CARBOPLATIN, Datopotamab deruxtecan
D926TC00001
Phase 3 small_molecule active
Quick answer
PEMETREXED, VINORELBINE, Rilvegostomig, MYCOPHENOLATE MOFETIL, ETOPOSIDE, CISPLATIN, INFLIXIMAB, CARBOPLATIN, Datopotamab deruxtecan for Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-positive result or high-risk pathological feature is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-positive result or high-risk pathological feature
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active